Global Health FY26 Annual Earnings Summary
3 quarters covered · ₹3,379 Cr revenue · ₹395 Cr PAT · 20.3% average EBITDA margin.
Quarter-by-quarter progression
Management promises made during the year
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q3 FY26Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q4 FY26Risks flagged during the year
Government business (CGHS/ECHS) takes 7-8 months for realization; new portal transition may cause further delays and require working capital investment.
Q2 FY26 · mediumMature hospitals' EBITDA grew only 2.2% YoY (adjusted) due to manpower cost increases and higher base from vector-borne diseases last year.
Q2 FY26 · mediumAttracting and retaining high-quality ethical clinical talent remains a challenge across the industry, especially in full-time model.
Q3 FY26 · mediumManagement acknowledged a 'war for talent' that could increase employee costs and pressure margins.
Q3 FY26 · mediumAnalyst raised concerns about insurer-hospital tiffs; management downplayed but noted ongoing commercial negotiations that could impact pricing.
Q3 FY26 · mediumManagement declined to provide a timeline for NOIA EBITDA breakeven, citing dependence on occupancy and case mix.
Q4 FY26 · mediumNew hospitals opening in Gurugram could increase competition for patients and clinical talent, potentially impacting occupancy and margins.
Q4 FY26 · mediumNoida's breakeven timeline depends on occupancy reaching 40-45%; delays in empanelments or patient flow could extend losses.
Q4 FY26 · mediumLarge greenfield projects (Delhi, Mumbai) may take 3+ years, with potential delays in regulatory approvals or construction, pushing revenue contribution beyond FY30.
Q4 FY26 · lowInternational patient revenue faces short-term challenges due to the situation in the Middle East, which could impact growth.
What changed through the year
Q2 FY26 · Noida hospital to ramp up with 550 beds fully operational
The Noida facility started with 226 beds in September; plans to add beds continuously, targeting full 550-bed capacity over coming quarters.
Q2 FY26 · Mumbai hospital expanded to 750 beds with ₹1,530 crore project cost
Board approved increased bed capacity from 500 to 750 at Oshiwara, with total project cost of ₹15,300 million including land and equipment.
Q2 FY26 · Guwahati hospital construction to begin after Bhoomi Pujan
Land acquisition completed for 400+ bed super-specialty hospital; construction to start post-October 2025 ceremony.
Q3 FY26 · ARP growth of 5-7% annually
Management expects ARP to grow 5-7% per year, with a more conservative internal projection of 3-5%.
Q3 FY26 · FY27 capex below ₹500 crore
Next year's capex is expected to be below ₹500 crore, significantly lower than the ~₹1,000 crore in FY26, as major NOIA construction is complete.
Q3 FY26 · NOIA losses expected to moderate
Management indicated that Q3 losses at NOIA are likely near peak and should reduce as the hospital ramps up.
Q4 FY26 · Noida breakeven expected in H2 FY27
Management expects Noida hospital to break even in the second half of FY27, with occupancy reaching 40-45%.
Q4 FY26 · FY27 capex guidance of ₹800-900 crore
Total capex for FY27 is expected to be in the range of ₹800-900 crore, with FY28 capex at ₹600-700 crore.
Q4 FY26 · Approximately 500 beds to be added with minimal capex
The company expects to add around 500 beds across existing hospitals with minimal capex investment in the short term.
Q4 FY26 · 2,700 beds through greenfield projects over 3-4 years
Medanta plans to add approximately 2,700 beds through five greenfield projects over the next 3-4 years, with total project capex of ~₹45,000 million over 5 years.